Literature DB >> 16135502

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.

Sandrine Faivre, Eric Raymond, Odile Casiraghi, Stéphane Temam, Patrice Berthaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16135502     DOI： 10.1200/JCO.2005.01.6055

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

1.  Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck.

Authors:  Amit Bahl; Naresh Kumar Panda; Arun Elangovan; Jaimanti Bakshi; Roshan Verma; Satyawati Mohindra; Rijuneeta Gupta; Arun Singh Oinam; Satinder Kaur; R K Vashishta; Sushmita Ghoshal
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-07-07

2.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 3.  Salivary gland stem cells: A review of development, regeneration and cancer.

Authors:  Elaine Emmerson; Sarah M Knox
Journal:  Genesis       Date:  2018-05-04       Impact factor: 2.487

4.  Adenoid Cystic Carcinoma of Vulva-11 Years' Single-Institution Experience.

Authors:  Leena Rose Johnson; Rema Prabhakaran Nair; Suchetha Sambasivan; Rari P Mony; Jayapriya Gangadharan; Aswin Kumar; Iqbal M Ahamed
Journal:  J Obstet Gynaecol India       Date:  2016-09-19

5.  Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.

Authors:  Osamu Tetsu; Janyaporn Phuchareon; Annie Chou; Darren P Cox; David W Eisele; Richard C K Jordan
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

6.  Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland.

Authors:  Lizette Vila; Hongyan Liu; Samer Z Al-Quran; Dominique P Coco; Hui-Jia Dong; Chen Liu
Journal:  Mod Pathol       Date:  2009-07-17       Impact factor: 7.842

7.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Authors:  S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

Review 8.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

9.  Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.

Authors:  Christoph Mundhenke; Marion Tina Weigel; Klarissa Hanja Sturner; Frank Roesel; Ivo Meinhold-Heerlein; Dirk O Bauerschlag; Christian Schem; Felix Hilpert; Walter Jonat; Nicolai Maass
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-09       Impact factor: 4.553

10.  Slug silencing inhibited perineural invasion through regulation of EMMPRIN expression in human salivary adenoid cystic carcinoma.

Authors:  Baolei Wu; Jianhua Wei; Zhiqiang Hu; Chun Shan; Lei Wang; Chenping Zhang; Xi Yang; Xinjie Yang; Delin Lei
Journal:  Tumour Biol       Date:  2015-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.